RDY · NYSE
Dr. Reddy's Laboratories (RDY) Stock Price & Fundamentals
Dr. Reddy's Laboratories (RDY) closed at $1,296.48 on Oct 9, 2026, down 0.47% from the previous close of $1,302.58.
Share price, past year
1Y +20.71%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,296.48 |
| Sep 30, 2026 | $1,322.82 |
| Aug 31, 2026 | $1,348.08 |
| Jul 31, 2026 | $1,337.53 |
| Jun 30, 2026 | $1,286.40 |
| May 29, 2026 | $1,297.81 |
| Apr 30, 2026 | $1,217.52 |
| Mar 31, 2026 | $1,240.42 |
| Feb 27, 2026 | $1,104.93 |
| Jan 30, 2026 | $1,028.20 |
| Dec 31, 2025 | $1,101.21 |
| Nov 28, 2025 | $1,104.79 |
| Oct 31, 2025 | $1,121.54 |
Key statistics
- Market cap
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- 834.7M
- Dividend yield
- —
- 52-week range
- $1,028.20 – $1,404.25
Market cap, P/E and dividend yield aren't shown for Dr. Reddy's Laboratories yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US, and report in Indian rupees.
Financials
Dr. Reddy's Laboratories reported revenue of ₹325.54B for fiscal 2025, up 16.61% from fiscal 2024.
Figures are in Indian rupees (INR), as Dr. Reddy's Laboratories reports them to the SEC.
Dr. Reddy's Laboratories earned net income of ₹56.54B in fiscal 2025, a net margin of 17.4%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Mar 31, 2025 | ₹325.54B | +16.6% | ₹56.54B | 17.4% | ₹67.78 | ₹18.92B |
| FY2024ended Mar 31, 2024 | ₹279.16B | +13.5% | ₹55.68B | 20.0% | ₹66.80 | ₹29.03B |
| FY2023ended Mar 31, 2023 | ₹245.88B | +14.7% | ₹45.07B | 18.3% | ₹54.17 | ₹47.55B |
| FY2022ended Mar 31, 2022 | ₹214.39B | +13.0% | — | — | ₹141.69 | ₹13.45B |
| FY2021ended Mar 31, 2021 | ₹189.72B | +8.7% | — | — | ₹103.65 | ₹25.96B |
| FY2020ended Mar 31, 2020 | ₹174.60B | +13.5% | — | — | ₹117.40 | ₹25.00B |
| FY2019ended Mar 31, 2019 | ₹153.85B | +8.3% | — | — | ₹113.09 | ₹21.75B |
| FY2018ended Mar 31, 2018 | ₹142.03B | +0.9% | ₹9.81B | 6.9% | ₹59.00 | ₹8.74B |
| FY2017ended Mar 31, 2017 | ₹140.81B | −9.0% | ₹12.04B | 8.6% | ₹72.09 | ₹9.24B |
| FY2016ended Mar 31, 2016 | ₹154.71B | — | ₹20.01B | 12.9% | ₹116.98 | ₹29.23B |
Company profile
- Name
- Dr. Reddy's Laboratories Ltd
- Ticker
- RDY
- Exchange
- NYSE
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 8-2-337, Road No.3 Banjara Hills, Hyderabad, 500-034
- Incorporated in
- K7
- Fiscal year ends
- March
- SEC CIK
- 0001135951
Recent SEC filings
- May 29, 2026
- Jun 6, 2025
- Jun 12, 2024
- Jun 13, 2023
- Jun 27, 2022
- Jun 30, 2021
- Jun 15, 2020
- Jun 3, 2019
Frequently asked questions
What is Dr. Reddy's Laboratories's stock price?
Dr. Reddy's Laboratories (RDY) closed at $1,296.48 on Oct 9, 2026, down 0.47% from the previous close of $1,302.58.
How much revenue does Dr. Reddy's Laboratories make?
Dr. Reddy's Laboratories reported revenue of ₹325.54B for fiscal 2025, up 16.61% from fiscal 2024.
Sources and methodology
Fundamentals come from Dr. Reddy's Laboratories Ltd's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures